Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $182.79.

Several research firms have issued reports on JAZZ. Piper Sandler restated an “overweight” rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Barclays reissued an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th.

Insider Activity

In other news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the sale, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at $1,189,587.54. This represents a 36.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,236 shares of company stock worth $3,956,190. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. increased its position in Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after acquiring an additional 507,234 shares in the last quarter. Nuveen LLC acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth approximately $62,362,000. Darwin Global Management Ltd. bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $59,668,000. Perpetual Ltd increased its holdings in shares of Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock valued at $118,212,000 after purchasing an additional 357,784 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $106.59 on Thursday. The company has a market cap of $6.57 billion, a price-to-earnings ratio of 15.01, a PEG ratio of 1.04 and a beta of 0.38. The business has a 50 day moving average price of $116.92 and a 200 day moving average price of $122.00. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.68 earnings per share. Research analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.